Company intelligence / Profile preview
Ambition Biopharma
Shanghai, Shanghai, Chinaambitionbiopharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ambition Biopharma is a clinical-stage biotechnology company focused on discovering and developing innovative small molecule drugs, primarily targeting B-cell related diseases and autoimmune conditions. Its lead program, ABT-101, is a highly selective BTK inhibitor currently undergoing clinical evaluation for both oncology and immunology indications.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ambition Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambition Biopharma.